TriSalus Life Sciences, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$13M
↑+59.8% +$5Mvs FY2024 (Q4)
Gross Profit
$11M
↑+62.4% +$4Mvs FY2024 (Q4)
Operating Income
$9M
↑+124.7% +$5Mvs FY2024 (Q4)
Net Income
$7M
↑+158.2% +$4Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $13M | $8M |
| COGS | $2M | $1M |
| Gross Profit | $11M | $7M |
| R&D | $3M | $3M |
| SG&A | $0 | $0 |
| D&A | $126K | $193K |
| Other OpEx | $0 | $0 |
| Operating Income | $9M | $4M |
| Interest Exp. | $1M | $1M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $7M | $3M |
| Tax | $0 | $0 |
| Net Income | $7M | $3M |
QuarterCharts · SEC EDGAR data · TLSI · Comparing FY2025 (Q4) vs FY2024 (Q4)